Insider Selling: OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells 50,012 Shares of Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 50,012 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.35, for a total transaction of $67,516.20. Following the transaction, the insider now directly owns 2,756,199 shares in the company, valued at approximately $3,720,868.65. The trade was a 1.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Friday, February 14th, Shalom Auerbach sold 100,000 shares of OS Therapies stock. The stock was sold at an average price of $2.84, for a total transaction of $284,000.00.
• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80.

OS Therapies Price Performance

Shares of NYSE OSTX opened at $1.25 on Friday. OS Therapies Inc has a 52-week low of $1.12 and a 52-week high of $7.00. The business’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.58.

Analyst Ratings Changes

A number of research firms recently commented on OSTX. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a report on Monday, April 7th. Lake Street Capital began coverage on OS Therapies in a report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 price target for the company. Finally, Maxim Group boosted their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, OS Therapies has an average rating of “Buy” and a consensus price target of $18.00.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.